Human IFN-gamma / IFNG Protein, premium grade
分子別名(Synonym)
Interferon-gamma ,Interferon-γ
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IFN-gamma, premium grade (IFG-H4211) is expressed from human 293 cells (HEK293). It contains AA Gln 24 - Gln 166 (Accession # P01579).
Predicted N-terminus: Gln 24
該產(chǎn)品是在我們嚴(yán)格的質(zhì)量控制體系下生產(chǎn)的,該體系包含一套全面的測試,包括無菌和內(nèi)毒素測試。在早期臨床前階段,產(chǎn)品性能經(jīng)過仔細(xì)驗(yàn)證和測試,以確保其與細(xì)胞培養(yǎng)用途或任何其他應(yīng)用的兼容性。當(dāng)準(zhǔn)備過渡到后期臨床階段時,我們還提供定制的GMP蛋白質(zhì)服務(wù),以滿足您的需求。我們將與您合作,根據(jù)您的要求定制和開發(fā)GMP級產(chǎn)品,該產(chǎn)品也符合細(xì)胞療法細(xì)胞制造中使用的原材料和輔助材料的要求。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 16.8 kDa. The protein migrates as 15 kDa, 19 kDa and 24 kDa±3 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
干擾素γ(IFN-γ/IFN)是一種二聚化的可溶性細(xì)胞因子,是II型干擾素的唯一成員。這種干擾素最初被稱為巨噬細(xì)胞激活因子,這個術(shù)語現(xiàn)在用來描述IFN-γ所屬的一個更大的蛋白質(zhì)家族。IFN-γ已用于各種臨床適應(yīng)癥。干擾素γ(IFNgamma)是免疫反應(yīng)和信號的中樞調(diào)節(jié)因子,通過Janus活化激酶(JAK)-信號轉(zhuǎn)導(dǎo)子和轉(zhuǎn)錄激活子(STAT)途徑。干擾素γ在激活對病毒和腫瘤的先天性和適應(yīng)性免疫反應(yīng)方面具有更廣泛的作用,部分是通過上調(diào)參與細(xì)胞周期調(diào)節(jié)、凋亡和抗原加工/呈遞的基因的轉(zhuǎn)錄。盡管如此,嚙齒動物和人類滋養(yǎng)層細(xì)胞對IFNG的反應(yīng)減弱,這反映了這些細(xì)胞對IFNG介導(dǎo)的主要組織相容性復(fù)合體(MHC)II類移植抗原表達(dá)的激活的抵抗力。
關(guān)鍵字: IFN-γ;IFN-γ蛋白;IFN-γ重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。